or Try an Advanced Search...

    Technical Analysis for NVCT - Nuvectis Pharma, Inc.

    Grade Last Price % Change Price Change
    F 6.49 0.86% 0.06
    NVCT closed down 10.57 percent on Wednesday, May 8, 2024, on 1.89 times normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NVCT trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.86%
    Down 3 Days in a Row Weakness 0.86%
    20 DMA Support Bullish -9.81%
    Spinning Top Other -9.81%
    Earnings Movers Other -9.81%
    50 DMA Resistance Bearish -14.22%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -14.22%
    Earnings Movers Other -14.22%
    Upper Bollinger Band Touch Strength -14.22%
    Crossed Above 20 DMA Bullish -20.33%
    Older End-of-Day Signals for NVCT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 8 minutes ago
    60 Minute Opening Range Breakout about 2 hours ago
    Up 2% about 3 hours ago
    Up 1% about 3 hours ago
    60 Minute Opening Range Breakdown about 4 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NVCT Chart by TradingView
    Basic chart:

    Profile

    Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Life Sciences Biology Treatment Of Cancer Tyrosine Kinase Oncogenes Cancer Research Small Molecule Kinase Proto Oncogene Tyrosine Protein Kinase Src

    Is NVCT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 8 Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes
    May 7 Nuvectis Pharma Q1 EPS of -$0.25
    May 7 Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
    Apr 17 Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
    Apr 8 Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
    Apr 2 5 Healthcare Stocks to Buy for 2024
    Mar 21 Insider Buys Additional US$51k In Nuvectis Pharma Stock
    Mar 15 Nuvectis Pharma to Present at the 36th Annual Roth Conference
    Mar 14 Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
    Mar 6 Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16
    See more NVCT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.65
    52 Week Low 5.92
    Average Volume 96,894
    200-Day Moving Average 9.82
    50-Day Moving Average 8.20
    20-Day Moving Average 6.84
    10-Day Moving Average 6.82
    Average True Range 0.79
    RSI (14) 42.20
    ADX 15.91
    +DI 22.01
    -DI 17.84
    Chandelier Exit (Long, 3 ATRs) 6.09
    Chandelier Exit (Short, 3 ATRs) 8.28
    Upper Bollinger Bands 7.76
    Lower Bollinger Band 5.91
    Percent B (%b) 0.28
    BandWidth 27.12
    MACD Line -0.25
    MACD Signal Line -0.36
    MACD Histogram 0.1103
    Fundamentals Value
    Market Cap 111.41 Million
    Num Shares 17.3 Million
    EPS -1.50
    Price-to-Earnings (P/E) Ratio -4.29
    Price-to-Sales 0.00
    Price-to-Book 7.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.32
    Resistance 3 (R3) 7.41 7.20 7.17
    Resistance 2 (R2) 7.20 6.98 7.16 7.12
    Resistance 1 (R1) 6.82 6.84 6.72 6.73 7.07
    Pivot Point 6.61 6.61 6.56 6.57 6.61
    Support 1 (S1) 6.23 6.39 6.13 6.14 5.79
    Support 2 (S2) 6.02 6.25 5.98 5.74
    Support 3 (S3) 5.64 6.02 5.69
    Support 4 (S4) 5.55